Uptake and safety of Sotrovimab for prevention of severe COVID-19 in a cohort and self-controlled case series study
Abstract Background Sotrovimab is a neutralising monoclonal antibody (nMAB) currently available to treat extremely clinically vulnerable COVID-19 patients in England. Trials have shown it to have mild to moderate side effects, however, evidence regarding its safety in real-world settings remains ins...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Nature Portfolio
2025-01-01
|
| Serier: | Communications Medicine |
| Online adgang: | https://doi.org/10.1038/s43856-024-00720-7 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|